Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: Usefulness of gelsolin protein

Pathology International

Volumn 59, Issue 11, 2009, Pages 797-803

  Ohnishi, Mihoko ^a   Matsumoto, Toshihide ^a   Nagashio, Ryo ^a,b   Kageyama, Taihei ^a   Utsuki, Satoshi ^a   Oka, Hidehiro ^a   Okayasu, Isao ^a   Sato, Yuichi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

2 D gel electrophoresis; Astrocytoma; Cerebrospinal fluid; Gelsolin; Immunohistochemistry

Indexed keywords

AGAROSE; FORMALDEHYDE; GELSOLIN; PARAFFIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CLASSIFICATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ASTROCYTOMA; BRAIN NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GELSOLIN; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 70350503051     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02447.x     Document Type: Article

References (24)

1. Nozaki M, Tada M, Kobayashi H et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neurooncology 1999 1 : 124 137.
2. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J. Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 2008 86 : 31 45.
3. Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2005 815 : 179 189. (Pubitemid 40126400)
4. Zougman A, Pilch B, Podtelejnikov A et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 2008 7 : 386 399.
5. Khwaja FW, Nolen JD, Mendrinos SE et al. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 2006 6 : 6277 6287.
6. Shores KS, Knapp DR. Assessment approach for evaluating high abundance protein depletion methods for cerebrospinal fluid (CSF) proteomic analysis. J Proteome Res 2007 6 : 3739 3751.
7. Khwaja FW, Reed MS, Olson JJ et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 2007 6 : 559 570.
8. Zheng PP, Luider TM, Pieters R et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003 62 : 855 862.
9. Oh-ishi M, Satoh M, Maeda T. Preparative two-dimensional gel electrophoresis with agarose gels in the first dimension for high molecular mass proteins. Electrophoresis 2000 21 : 1653 1669.
10. Raymackers J, Daniels A, De Brabandere V et al. Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/ionization-mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry. Electrophoresis 2000 21 : 2266 2283.
11. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003 118 : 140 146. (Pubitemid 37238996)
12. Shieh DB, Chen IW, Wei TY et al. Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol 2006 42 : 599 606.
13. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB. Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 2001 65 : 11 21.
14. Gay F, Estornes Y, Saurin JC et al. In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol 2008 39 : 1420 1430.
15. Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999 40 : 14 19.
16. Tanaka M, Mullauer L, Ogiso Y et al. Gelsolin: Candidate for suppressor of human bladder cancer. Cancer Res 1995 55 : 3228 3232.
17. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY. Downregulation of and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 2004 19 : 218 224.
18. Visapaa H, Bui M, Huang Y et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003 61 : 845 850.
19. Noske A, Denkert C, Schober H et al. Loss of gelsolin expression in human ovarian carcinoma. Eur J Cancer 2005 41 : 461 469.
20. Tanaka H, Shirkoohi R, Nakagawa K et al. siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer 2006 118 : 1680 1691.
21. Yang J, Tan D, Asch HL et al. Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer 2004 46 : 29 42.
22. Rao J, Seligson D, Visapaa H et al. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 2002 95 : 1247 1257.
23. Thor AD, Edgerton SM, Liu S, Moore DH 2nd., Kwiatkowski DJ. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 2001 7 : 2415 2424.
24. Gdynia G, Grund K, Eckert A et al. Basal caspase activity promotes migration and invasiveness in glioblastoma cells. Mol Cancer Res 2007 5 : 1232 1240.